Clinical Significance of Prothrombin Time in Cholangiocarcinoma Patients with Surgeries

Table 4

Analysis of overall survival (OS) and recurrence-free survival (RFS) in different groups.

Variable	Category	Mean OS	P value	Mean RFS	P value
Gender	Male/Female	18.60vs23.62	0.2993†	13.20vs18.08	0.3481†
Age	<64/≥64	25.68vs16.59	0.0163†	19.69vs11.58	0.0076†
PLT, 10^9/L	<258.67/≥258.67	18.91vs26.36	0.1127	13.97vs19.38	0.2554
PDW, fL	<17.99/>=17.99	20.13vs22.82	0.8045†	14.76vs17.08	0.6263
MPV, fL	<12.46/>=12.46	21.64vs18.41	0.4936	15.58vs14.70	0.8530
LYM, 10^9/L	<1.5/>=1.5	19.12vs25.76	0.1575	14.27vs18.5	0.3745
NEU, 10^9/L	<7.12/>=7.12	21.31vs19.37	0.6817	15.95vs13.61	0.6240
PLR	<240.18/>=240.18	20.50vs21.87	0.8620†	14.92vs16.79	0.7319†
NLR	<6.17/>=6.17	22.79vs14.7	0.0894	16.87vs10.65	0.1972
APTT, s	<30.8/≥30.8	20.36vs22.12	0.7114	15.25vs15.66	0.9304
PT, s	<12.3/≥12.3	23.03vs14.38	0.0250†	17.78vs8.30	0.0511†
INR	<1.07/≥1.07	23.03vs14.38	0.0250†	17.78vs8.30	0.0511†
FIB, g/L	<4.49/≥4.49	22.31vs16.48	0.7572†	16.74vs11.31	0.8829†
TT, s	<18.75/≥18.75	20.05vs23.19	0.5128	14.26vs18.75	0.3523
DD, ug/mL	<1.11/≥1.11	22.05vs17.63	0.3354	16.68vs11.93	0.3047
ALB, g/L	<35/≥35	15.99vs24.64	0.0725†	9.65vs19.87	0.0426†
CRP, mg/L	<10/≥10	23.29vs19.80	0.0495†	16.96vs14.69	0.0235†
GPS	0/1-2	22.68vs20.29	0.0669†	17.12vs14.85	0.0238†
CA199, U/ml	<37/>=37	24.07vs19.24	0.2715	17.33vs14.40	0.5086
CA125, U/ml	<36.49/≥36.49	20.60vs21.30	0.8750	15.09vs15.93	0.8515
CEA, ng/ml	<5.1/≥5.1	22.34vs17.82	0.6709†	16.27vs13.56	0.7181†
Differentiation	Middle-High/Low	25.94vs10.74	0.0001†	20.26vs 5.69	0.0001†
Lymph	(+)/(-)	17.41vs23.64	0.1302	11.57vs18.49	0.0955
Nerve	(+)/(-)	19.07vs24.85	0.1965	13.06vs20.64	0.0920
Stage	I-II/III-IVA	23.40vs14.15	0.0430†	18.41vs 7.45	0.0199†

†: rank sum test is used due to the uniform variance. The variance of other groups is uniform; therefore one-way ANOVA is used. PLT, platelet count, PDW, platelet distribution width, MPV, mean platelet volume, LYM, lymphocyte count NEU, neutrophil count, PLR, platelet-lymphocyte ratio, NLR, neutrophil-lymphocyte ratio, ALB, albumin, CRP, C-reactive protein, GPS, Glasgow Prognostic Score, APTT, activated partial thromboplastin time, PT, prothrombin time, INR, international normalized ratio, FIB, fibrinogen, TT, thrombin time, DD: D-dimer, Lymph: lymph node metastasis, and Nerve, nerve invasion. OS, overall survival and RFS, recurrence-free survival.